Another prospective head-to-head comparison of [18F]fluorocholine and [18F]F-PSMA-1007 PET/CT in 40 patients with biochemically relapsed prostate cancer (PSA < 2.0 ng/mL) demonstrated a clear advantage of [18F]F-PSMA-1007 over [18F]fluorocholine for the detection of recurrent lesions (60% vs. 5%), as determined by trained nuclear medicine physicians [61]. The gene discussed is FOLH1; the disease is prostate cancer.